-
Pfizer Inc. Reports Q2 2023 Revenues, Signals Shift Beyond COVID-19 Products
•
US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the second quarter of 2023, reporting revenues of USD 12.7 billion over the three months, marking a year-on-year (YOY) decrease of 53%. The decline is attributed to the loss of sales from Paxlovid (nirmatrelvir, ritonavir) and Comirnaty…
-
MSD’s Q2 2023 Earnings: Keytruda and Gardasil Drive Growth Amid COVID-19 Sales Decline
•
US-based major Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has released its financial results for the second quarter of 2023, showing a 7% year-on-year (YOY) growth in worldwide sales, reaching USD 15 billion in constant exchange rates. The pharmaceuticals business reached USD 13.457 billion, up 8% YOY, while Animal…
-
WuXi AppTec Reports 6.28% Revenue Growth and 23.67% Net Profit Increase in H1 2023
•
China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for the first half of 2023, recording revenues of RMB 18.871 billion (USD 2.6 billion), representing a 6.28% year-on-year (YOY) growth. Net profits reached RMB 4.761 billion (USD 666 million), marking a significant increase of 23.67%…
-
HutchMed Ltd Reports 164% Revenue Growth and Clinical Updates for H1 2023
•
China-based HutchMed Ltd (NASDAQ: HCM; HKG: 0013) has announced its unaudited financial results for the six months ended June 30, 2023, along with updates on key clinical and commercial developments. The company reported a significant increase in total revenues, which jumped by 164% (173% at constant exchange rate) to USD…
-
Akeso Biopharma Reports First Positive Earnings in H1 2023 Financial Results
•
Akeso Biopharma (HKG: 9926) has released its financial report for the first half of 2023, marking the company’s first period of positive earnings. The firm expects to achieve profits of RMB 2.3 billion (USD 321.8 million) during this period. Contributing Factors to Positive EarningsThe positive earnings are attributed to several…
-
AstraZeneca’s H1 2023 Financials Show 4% YOY Revenue Growth, Oncology and R&I Drive Sales
•
UK-based pharmaceutical giant AstraZeneca plc (AZ, NASDAQ: AZN) has announced its financial results for the first half of 2023, marking another quarter of robust growth in both top-line and bottom-line figures. Global revenues for the six-month period increased by 4% year-on-year (YOY) in constant exchange rate terms to USD 22.295…
-
Sanofi Reports 3.3% YOY Sales Growth in Q2 2023, Driven by Vaccines and Dupixent
•
France-based Sanofi (NASDAQ: SNY) has released its financial results for the second quarter of 2023, reporting a 3.3% year-on-year (YOY) increase in global sales, reaching EUR 9.965 billion (USD 10.98 billion) in constant exchange rate terms. Key growth drivers included sales from vaccines and the anti-allergy drug Dupixent (dupilumab). Dupixent’s…
-
Bristol-Myers Squibb Q2 2023 Results Miss Estimates, Full-Year Guidance Revised Downward
•
US pharmaceutical company Bristol-Myers Squibb (BMS; NYSE: BMY) has released its financial report for the second quarter of 2023, which showed performance below expectations and led to a downward revision in full-year guidance. Revenues for the quarter decreased by 5% year-on-year (YOY) in constant exchange rate terms to USD 11.2…
-
Roche Group’s H1 2023 Financial Report: Pharmaceuticals Grow While Diagnostics Dip
•
Swiss pharmaceutical giant Roche Group (SWX: ROG) has released its half-yearly financial report for 2023, showing a -2% year-on-year (YOY) decline in group sales to CHF 29.8 billion (USD 34.5 billion) in constant exchange rate terms. Within the group, Pharmaceuticals saw an 8% YOY increase to CHF 22.7 billion (USD…
-
Thermo Fisher Scientific Reports Q2 2023 Revenue Dip, Adjusts Full-Year Forecast
•
US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO) has released its financial results for the second quarter of 2023, showing a 3% year-on-year (YOY) decrease in revenues in constant currency terms, amounting to USD 10.69 billion. CEO Marc Casper attributed the decline to a more challenging macroeconomic environment,…
-
GSK Reports 4% YOY Sales Growth in Q2 2023, Upgrades Full-Year Guidance
•
UK-based pharmaceutical giant GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial report for the second quarter of 2023, demonstrating a robust performance with sales revenues increasing by 4% year-on-year (YOY) in constant currency terms to GBP 7.178 billion (USD 9.3 billion). Excluding COVID-19-related sales, the growth was even more…
-
Biogen’s Q2 2023 Report Reveals Struggles with Aduhelm and 1,000 Job Cuts
•
US-based biopharmaceutical company Biogen (NASDAQ: BIIB) has released its financial report for the second quarter of 2023, which shows the firm continuing to face challenges due to the underwhelming market entry of its Alzheimer’s therapy, Aduhelm (aducanumab). In response, Biogen announced plans to make 1,000 job cuts as part of…
-
Johnson & Johnson Reports 7.5% YOY Sales Growth in Q2 2023, Driven by Pharma and Devices
•
Johnson & Johnson (J&J; NYSE: JNJ) has published its financial results for the second quarter of 2023, reporting robust sales growth of 7.5% year-on-year (YOY) in constant currency terms, reaching USD 25.5 billion. The performance was driven by all business segments, with the pharmaceutical unit Janssen expanding by 3.8% YOY…
-
Abbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip
•
US-based life sciences firm Abbott (NYSE: ABT) has released its financial results for the second quarter of 2023, reporting strong revenue and profit growth that exceeded analysts’ consensus. Despite a significant drop in sales of COVID-19 diagnostics from USD 2.3 billion a year ago to just USD 263 million in…
-
Novartis Q2 2023 Results Exceed Expectations with 9% YOY Sales Growth
•
Swiss pharmaceutical major Novartis AG (NYSE: NVS) has reported its financial results for the second quarter of 2023, with both sales and profits surpassing analyst forecasts. Net sales for the quarter reached USD 13.622 billion, marking a 9% year-on-year (YOY) increase in constant currency terms. Core net income also saw…
-
Harbour BioMed Reports First-Ever Profit in H1 2023 Interim Financial Results
•
Harbour BioMed (HKG: 2142), a biotech company with operations in Suzhou, China, Cambridge in the US, and the Netherlands, has announced its interim financial results for the period ending June 30, 2023. In a preliminary review of unaudited figures, the company reported a net profit for the first time, expecting…
-
Lundbeck A/S Reports Record Quarterly Revenue in Q1 2023 with 11% YOY Increase
•
Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) has released its financial report for the first quarter of 2023, highlighting an 11% year-on-year (YOY) increase in global sales revenues in constant exchange rate terms, reaching DKK 5.044 billion (USD 731.2 million). This figure marks the highest quarterly revenue in the company’s…
-
Bayer Q1 2023 Financial Report: Sales Dip Amid Regional Challenges and COVID-19 Impact
•
Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2023, revealing a 1.1% decrease in group sales, excluding exchange effects, to €14.389 billion (USD 15.74 billion). Net profits fell 33.8% year-on-year (YOY) to €2.178 billion, reflecting the ongoing challenges in the pharmaceutical industry. Pharmaceuticals Unit…
-
Zai Lab Limited Reports Q1 2023 Financial Results and Product Highlights
•
China-based Zai Lab Limited (NASDAQ: ZLAB; HKG: 9688) has announced its financial results for the first quarter of 2023, along with recent product highlights and corporate updates. The company reported total product revenues of USD 62.8 million for the quarter, marking a 36% year-on-year (YOY) growth. Product Sales and ContributionsThe…
-
Organon Reports Q1 2023 Revenue Growth, Highlights Women’s Health and Biosimilars Progress
•
Organon (NYSE: OGN) has released its financial report for the first quarter of 2023, announcing a 3% year-on-year (YOY) increase in revenues, excluding foreign exchange effects, amounting to USD 1.54 billion. This growth was driven by a 3% increase in Women’s Health revenues, a 20% increase in Biosimilars, and a…
